Research Article
Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma
Table 3
The influence of MMP genotypes on time to progression and overall survival in MPM patients, adjusted for clinical variables.
| Gene | Genotype | Time to progression | HR (95% CI) | | Overall survival | HR (95% CI) | | Median (25%–75%) | Median (25%–75%) |
| MMP2 | | | | | | | | rs243865 | CC | 8.83 (6.43–15.03) | Ref. | | 17.43 (10.60–27.27) | Ref. | | CT | 10.17 (6.00–16.33) | 0.88 (0.63–1.22) | 0.437 | 17.47 (9.47–31.17) | 0.96 (0.68–1.36) | 0.826 | TT | 14.97 (8.20–44.57) | 0.54 (0.17–1.75) | 0.305 | 30.00 (22.03–30.00) | 0.44 (0.11–1.81) | 0.255 | CT + TT | 10.20 (6.27–16.33) | 0.85 (0.61–1.18) | 0.334 | 18.07 (9.63–31.17) | 0.92 (0.66–1.30) | 0.653 | rs243849 | CC | 9.87 (6.13–16.67) | Ref. | | 19.10 (9.83–28.13) | Ref. | | CT | 8.67 (6.67–14.30) | 1.30 (0.91–1.86) | 0.144 | 16.23 (10.80–29.03) | 1.26 (0.86–1.85) | 0.227 | TT | 7.33 (3.27–11.80) | 2.16 (1.02–4.55) | 0.043 | 17.63 (7.33–36.73) | 1.18 (0.51–2.72) | 0.698 | CT + TT | 8.67 (6.60–14.30) | 1.38 (0.98–1.94) | 0.064 | 16.63 (10.80–30.27) | 1.25 (0.87–1.80) | 0.225 | rs7201 | AA | 9.27 (6.37–16.93) | Ref. | | 16.23 (10.63–28.03) | Ref. | | AC | 10.00 (6.73–15.03) | 0.87 (0.61–1.24) | 0.441 | 19.30 (10.80–30.00) | 0.89 (0.62–1.29) | 0.547 | CC | 8.00 (5.50–12.63) | 1.15 (0.73–1.80) | 0.551 | 14.20 (9.23–26.17) | 1.20 (0.74–1.95) | 0.467 | AC + CC | 9.80 (6.43–14.57) | 0.93 (0.67–1.30) | 0.684 | 18.07 (9.63–29.03) | 0.96 (0.67–1.36) | 0.803 |
| MMP9 | | | | | | | | rs17576 | AA | 9.27 (6.13–13.53) | Ref. | | 13.57 (9.83–23.90) | Ref. | | AG | 10.73 (6.80–18.47) | 0.84 (0.60–1.17) | 0.303 | 21.20 (12.17–32.53) | 0.72 (0.50–1.03) | 0.070 | GG | 8.50 (6.00–16.67) | 1.17 (0.69–1.98) | 0.558 | 16.63 (8.27–26.60) | 0.96 (0.54–1.68) | 0.881 | AG + GG | 10.00 (6.67–16.90) | 0.89 (0.65–1.23) | 0.478 | 19.30 (11.33–31.17) | 0.76 (0.54–1.06) | 0.106 | rs2250889 | CC | 10.03 (6.73–16.67) | Ref. | | 19.10 (11.33–30.00) | Ref. | | CG | 6.07 (4.07–7.90) | 2.32 (1.34–4.03) | 0.003 | 9.23 (4.53–14.20) | 2.52 (1.42–4.46) | 0.002 | rs17577 | GG | 10.00 (6.60–16.33) | Ref. | | 18.07 (10.60–28.30) | Ref. | | GA | 8.33 (5.50–14.57) | 1.20 (0.84–1.72) | 0.319 | 17.63 (9.47–32.87) | 0.82 (0.56–1.20) | 0.311 | AA | 8.83 (8.00–19.43) | 1.02 (0.32–3.25) | 0.977 | 13.50 (9.97–25.93) | 1.58 (0.49–5.04) | 0.444 | GA + AA | 8.50 (5.53–14.57) | 1.19 (0.84–1.68) | 0.339 | 17.63 (9.63–32.53) | 0.85 (0.59–1.24) | 0.403 | rs20544 | CC | 7.53 (5.53–11.53) | Ref. | | 13.50 (8.13–21.20) | Ref. | | CT | 10.93 (7.37–19.97) | 0.60 (0.40–0.90) | 0.014 | 20.67 (11.33–32.53) | 0.59 (0.39–0.91) | 0.018 | TT | 9.40 (6.27–14.30) | 0.67 (0.43–1.03) | 0.069 | 15.40 (10.80–25.67) | 0.70 (0.44–1.11) | 0.132 | CT + TT | 10.13 (6.73–16.20) | 0.62 (0.43–0.92) | 0.016 | 19.30 (10.80–31.17) | 0.63 (0.42–0.95) | 0.025 |
| MMP14 | | | | | | | | rs1042703 | TT | 9.27 (6.67–16.33) | Ref. | | 17.50 (9.97–29.13) | Ref. | | TC | 10.17 (6.27–14.53) | 1.36 (0.94–1.96) | 0.100 | 19.30 (9.47–29.03) | 1.25 (0.87–1.81) | 0.229 | CC | 8.70 (5.13–16.20) | 2.09 (1.06–4.12) | 0.032 | 12.70 (7.07–20.60) | 2.14 (1.12–4.06) | 0.020 | TC + CC | 10.17 (6.03–14.97) | 1.44 (1.01–2.03) | 0.042 | 17.63 (8.30–28.30) | 1.36 (0.97–1.92) | 0.076 | rs1042704 | GG | 9.80 (6.73–14.90) | Ref. | | 17.50 (10.80–31.17) | Ref. | | GA | 8.30 (5.70–16.20) | 1.05 (0.74–1.49) | 0.780 | 17.47 (9.10–24.23) | 1.40 (0.98–2.00) | 0.068 | AA | 7.87 (6.00–16.90) | 0.90 (0.45–1.82) | 0.777 | 20.27 (13.57–25.93) | 1.22 (0.59–2.53) | 0.598 | GA + AA | 8.30 (5.93–16.90) | 1.03 (0.74–1.42) | 0.881 | 18.07 (9.63–24.57) | 1.37 (0.97–1.92) | 0.072 | rs743257 | CC | 9.87 (7.07–14.07) | Ref. | | 13.50 (9.97–27.27) | Ref. | | CT | 9.40 (5.97–19.43) | 1.08 (0.72–1.64) | 0.700 | 15.40 (6.80–28.13) | 0.98 (0.65–1.49) | 0.931 | TT | 9.70 (6.60–14.53) | 1.15 (0.75–1.76) | 0.535 | 20.17 (12.53–31.17) | 0.87 (0.56–1.36) | 0.544 | CT + TT | 9.43 (6.07–16.33) | 1.11 (0.76–1.63) | 0.588 | 19.30 (9.83–30.27) | 0.93 (0.63–1.37) | 0.722 |
|
|